Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility

Pittsburgh compound B or [11C]PIB is an amyloid imaging agent which shows a clear differentiation between subjects with Alzheimer's disease (AD) and controls. However the observed signal difference in other forms of dementia such as dementia with Lewy bodies (DLB) is smaller, and mild cognitively impaired (MCI) subjects and some healthy elderly normals may show intermediate levels of [11C]PIB binding. The cerebellum, a commonly used reference region for non-specific tracer uptake in [11C]PIB studies in AD may not be valid in Prion disorders or monogenic forms of AD. The aim of this work was to: 1-compare methods for generating parametric maps of [11C]PIB retention in tissue using a plasma input function in respect of their ability to discriminate between AD subjects and controls and 2-estimate the test-retest reproducibility in AD subjects. 12 AD subjects (5 of which underwent a repeat scan within 6 weeks) and 10 control subjects had 90 minute [11C]PIB dynamic PET scans, and arterial plasma input functions were measured. Parametric maps were generated with graphical analysis of reversible binding (Logan plot), irreversible binding (Patlak plot), and spectral analysis. Between group differentiation was calculated using Student's t-test and comparisons between different methods were made using p values. Reproducibility was assessed by intraclass correlation coefficients (ICC). We found that the 75 min value of the impulse response function showed the best group differentiation and had a higher ICC than volume of distribution maps generated from Logan and spectral analysis. Patlak analysis of [11C]PIB binding was the least reproducible.

[1]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Different patterns of PIB uptake in AD patients , 2005 .

[3]  Guy Marchal,et al.  Automated multi-modality image registration based on information theory , 1995 .

[4]  R. Boellaard,et al.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[6]  J. Mann,et al.  Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease , 2008, Journal of Nuclear Medicine.

[7]  W. Klunk,et al.  Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. , 2002, Journal of molecular neuroscience : MN.

[8]  W. Klunk,et al.  Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease , 2002, Journal of Molecular Neuroscience.

[9]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Alexander Hammers,et al.  Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine test–retest data , 2007, NeuroImage.

[11]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  F. Turkheimer,et al.  The Use of Spectral Analysis to Determine Regional Cerebral Glucose Utilization with Positron Emission Tomography and [18F]Fluorodeoxyglucose: Theory, Implementation, and Optimization Procedures , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  Gunnar Antoni,et al.  Unidirectional Influx and Net Accumulation of PIB , 2008, The open neuroimaging journal.

[14]  S. DeKosky,et al.  P1-256: Cerebellar amyloid in a case of early-onset dementia with a presenilin-1 mutation: Correlation to clinical phenotype , 2008, Alzheimer's & Dementia.

[15]  Brian J Bacskai,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[16]  Nelleke Tolboom,et al.  Multi-input spectral analysis for assessing cerebral uptake of labelled metabolites: Validation and application to [11C]PIB and [18F]FDDNP studies , 2007 .

[17]  W. Klunk,et al.  Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain , 2004 .

[18]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  W. Klunk,et al.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.

[21]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  P. Lantos,et al.  Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneity. , 2006, Brain : a journal of neurology.

[23]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[24]  R. Hinz,et al.  Determination of tracer arrival delay with spectral analysis , 2004, IEEE Transactions on Nuclear Science.

[25]  Parametric imaging of [11C]PIB studies using spectral analysis , 2005 .

[26]  Yun Zhou,et al.  Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.

[27]  P M Bloomfield,et al.  The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. , 1991, Medical progress through technology.

[28]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[29]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  Nelleke Tolboom,et al.  Image-derived input functions for PET brain studies , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  L. Lemieux,et al.  Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space , 2007, Human brain mapping.

[34]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[35]  Brian J Bacskai,et al.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Nelleke Tolboom,et al.  Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.

[37]  A. Burns Clinical diagnosis of Alzheimer's disease , 1991 .

[38]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[39]  W. Klunk,et al.  Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. , 2004, Current pharmaceutical design.

[40]  L. Duchen,et al.  Cerebral amyloid in human prion disease , 1993, Neuropathology and applied neurobiology.

[41]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[42]  Marie-Claude Asselin,et al.  Quantification of PET Studies with the Very High-Affinity Dopamine D2/D3 Receptor Ligand [11C]FLB 457: Re-Evaluation of the Validity of using a Cerebellar Reference Region , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  Guy Marchal,et al.  Automated multi-moda lity image registration based on information theory , 1995 .

[44]  Michel Defrise,et al.  Exact and approximate rebinning algorithms for 3-D PET data , 1997, IEEE Transactions on Medical Imaging.

[45]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.